Medicus Pharma Ltd.

Medicus Pharma Ltd. (MDCX) priced its initial public offering on Nov 15, 2024 at $4.12 per share, raising $4M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $44.7M. Maxim Group was lead-left underwriter, joined by Brookline and Arcadia. Bennett Jones and Paul, Weiss advised the company and Pryor Cashman advised the underwriters.

Medicus Pharma Ltd. is a biotech and life sciences company developing SkinJect, a doxorubicin tip-loaded microneedle array combination product candidate for basal cell carcinoma, a form of skin cancer.

Status

IPO

Ticker

MDCX

Exchange

Nasdaq Capital Market

Priced

Nov 15, 2024

IPO price

$4.12

Raised

$4M

Market cap at IPO price

$44.7M

First filed

May 29, 2024

Underwriters

Maxim Group, Brookline and Arcadia

Company counsel

Bennett Jones and Paul, Weiss

Underwriters' counsel

Pryor Cashman

Sector

Biotech & pharma

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.